Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342796 | 1.00 | ESR2 (0.61) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL5344147 | 1.00 | ESR2 (0.61) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL5344139 | 1.00 | ESR2 (0.61) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL5339121 | 0.89 | ESR2 (0.60) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL5339801 | 0.89 | ESR2 (0.60) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL5339804 | 0.89 | ESR2 (0.60) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL5339111 | 0.89 | ESR2 (0.60) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL14516385 | 0.89 | ESR2 (0.46) | ESR2PTGS2 | |
| SCHEMBL14516402 | 0.89 | ESR2 (0.46) | ESR2PTGS2 | |
| SCHEMBL5339253 | 0.88 | ESR2 (0.61) | ESR2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199154-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2007-04-03 | — | — | US | disclosed |
| US-20050261245-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261245-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | PTGIS, PTGS1, PTGS2 | ESR2 1641/4885CA12 4028/4885CA1 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.